- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 591931, 9 pages
The Role of MicroRNAs in Cancer Susceptibility
1Dipartimento di Medicina Sperimentale e Clinica, Università “Magna Graecia” di Catanzaro, 88100 Catanzaro, Italy
2Unità Operativa di Genetica Medica, Università “Magna Graecia” di Catanzaro, 88100 Catanzaro, Italy
3Dipartimento di Medicina Molecolare, Università di Roma “Sapienza”, 00161 Roma, Italy
4Dipartimento di Scienze della Salute, Università “Magna Graecia” di Catanzaro, 88100 Catanzaro, Italy
5Centro Oncologico Fondazione T. Campanella, 88100 Catanzaro, Italy
Received 19 December 2012; Accepted 14 February 2013
Academic Editor: Anna Di Gregorio
Copyright © 2013 Rodolfo Iuliano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- V. N. Kim, J. Han, and M. C. Siomi, “Biogenesis of small RNAs in animals,” Nature Reviews Molecular Cell Biology, vol. 10, no. 2, pp. 126–139, 2009.
- R. I. Gregory, K. P. Yan, G. Amuthan, et al., “The Microprocessor complex mediates the genesis of microRNAs,” Nature, vol. 432, no. 7014, pp. 235–240, 2004.
- J. Brennecke, A. Stark, R. B. Russell, and S. M. Cohen, “Principles of microRNA-target recognition,” PLoS Biology, vol. 3, no. 3, article e85, 2005.
- S. M. Johnson, H. Grosshans, J. Shingara et al., “RAS is regulated by the let-7 microRNA family,” Cell, vol. 120, no. 5, pp. 635–647, 2005.
- A. Cimmino, G. A. Calin, M. Fabbri et al., “miR-15 and miR-16 induce apoptosis by targeting BCL2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 13944–13949, 2005.
- V. Olive, M. J. Bennett, J. C. Walker et al., “miR-19 is a key oncogenic component of mir-17-92,” Genes and Development, vol. 23, no. 24, pp. 2839–2849, 2009.
- R. Visone, L. Russo, P. Pallante et al., “MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle,” Endocrine-Related Cancer, vol. 14, no. 3, pp. 791–798, 2007.
- F. Paduano, V. Dattilo, D. Narciso, et al., “Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328,” The FEBS Journal, vol. 280, no. 2, pp. 401–412, 2013.
- R. Garzon, G. A. Calin, and C. M. Croce, “MicroRNAs in cancers,” Annual Review of Medicine, vol. 60, pp. 167–179, 2009.
- M. Fabbri, N. Valeri, and G. A. Calin, “MicroRNAs and genomic variations: from proteus tricks to prometheus gift,” Carcinogenesis, vol. 30, no. 6, pp. 912–917, 2009.
- K. Jazdzewski, E. L. Murray, K. Franssila, B. Jarzab, D. R. Schoenberg, and A. De La Chapelle, “Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 20, pp. 7269–7274, 2008.
- M. Wang, H. Chu, P. Li, et al., “Genetic variants in miRNAs predict bladder cancer risk and recurrence,” Cancer Research, vol. 72, no. 23, pp. 6173–6182, 2012.
- R. W. Lung, X. Wang, and J. H. Tong, “A single nucleotide polymorphism in microRNA-146a is associated with the risk for nasopharyngeal carcinoma,” Molecular Carcinogenesis, 2012.
- C. Pastrello, J. Polesel, L. D. Puppa, A. Viel, and R. Maestro, “Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients,” Carcinogenesis, vol. 31, no. 12, pp. 2124–2126, 2010.
- I. Catucci, R. Yang, P. Verderio et al., “Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases,” Human Mutation, vol. 31, no. 1, pp. E1052–E1057, 2010.
- A. I. Garcia, D. G. Cox, L. Barjhoux, et al., “The rs2910164:G >C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers,” Human Mutation, 2011.
- H. Lian, L. Wang, and J. Zhang, “Increased risk of breast cancer associated with CC genotype of Has-miR-146a Rs2910164 polymorphism in Europeans,” PLoS ONE, vol. 7, no. 2, Article ID e31615, 2012.
- Z. Wang, Y. Cao, C. Jiang, G. Yang, J. Wu, and Y. Ding, “Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis,” PLoS ONE, vol. 7, no. 6, Article ID e40039, 2012.
- Z. Hu, J. Chen, T. Tian et al., “Genetic variants of miRNA sequences and non-small cell lung cancer survival,” Journal of Clinical Investigation, vol. 118, no. 7, pp. 2600–2608, 2008.
- S. Vinci, S. Gelmini, N. Pratesi, et al., “Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 12, pp. 2073–2080, 2011.
- B. C. Christensen, M. Avissar-Whiting, L. G. Ouellet et al., “Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer,” Clinical Cancer Research, vol. 16, no. 14, pp. 3713–3720, 2010.
- K. T. Min, J. W. Kim, Y. J. Jeon, et al., “Association of the miR-146aC>G, 149C>T, 196a2C>T, and 499A>G polymorphisms with colorectal cancer in the Korean population,” Molecular Carcinogenesis, vol. 51, no. 1, pp. E65–E73, 2012.
- Z. Hu, J. Liang, Z. Wang et al., “Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women,” Human Mutation, vol. 30, no. 1, pp. 79–84, 2009.
- H. Chu, M. Wang, D. Shi et al., “Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies,” PLoS ONE, vol. 6, no. 3, Article ID e18108, 2011.
- Y. Ye, K. K. Wang, J. Gu et al., “Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk,” Cancer Prevention Research, vol. 1, no. 6, pp. 460–469, 2008.
- R. A. Smith, D. J. Jedlinski, P. N. Gabrovska, S. R. Weinstein, L. Haupt, and L. R. Griffiths, “A genetic variant located in miR-423 is associated with reduced breast cancer risk,” Cancer Genomics Proteomics, vol. 9, no. 3, pp. 115–118, 2012.
- J. Xing, S. Wan, F. Zhou, et al., “Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer,” Cancer Epidemiology, Biomarkers & Prevention, vol. 21, no. 1, pp. 217–227, 2012.
- F. Wang, G. Sun, Y. Zou, Y. Li, L. Hao, and F. Pan, “Association of microRNA-499 rs3746444 polymorphism with cancer risk: evidence from 7188 cases and 8548 controls,” PLoS ONE, vol. 7, no. 9, Article ID e45042, 2012.
- B. Zhou, K. Wang, Y. Wang et al., “Common genetic polymorphisms in pre-microRNAs and risk of cervical squamous cell carcinoma,” Molecular Carcinogenesis, vol. 50, no. 7, pp. 499–505, 2011.
- M. Lin, J. Gu, C. Eng, et al., “Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients,” Clinical Cancer Research, vol. 18, no. 14, pp. 3982–3991, 2012.
- B. M. Ryan, A. C. McClary, N. Valeri, et al., “rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer,” PLoS ONE, vol. 7, no. 5, Article ID e36306, 2012.
- A. J. Huang, K. D. Yu, J. Li, L. Fan, and Z. M. Shao, “Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes,” PLoS ONE, vol. 7, no. 5, Article ID e35252, 2012.
- R. Yang, B. Schlehe, K. Hemminki et al., “A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk,” Breast Cancer Research and Treatment, vol. 121, no. 3, pp. 693–702, 2010.
- I. Catucci, P. Verderio, S. Pizzamiglio, et al., “The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians,” Breast Cancer Research and Treatment, vol. 133, no. 2, pp. 805–807, 2012.
- R. Yang and B. Burwinkel, “A bias in genotyping the miR-27a rs895819 and rs11671784 variants,” Breast Cancer Research and Treatment, vol. 134, no. 2, pp. 899–901, 2012.
- D. Shi, P. Li, L. Ma, et al., “A genetic variant in pre-miR-27a is associated with a reduced renal cell cancer risk in a Chinese population,” PLoS ONE, vol. 7, no. 10, Article ID e46566, 2012.
- Q. Sun, H. Gu, Y. Zeng et al., “Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression,” Cancer Science, vol. 101, no. 10, pp. 2241–2247, 2010.
- L. J. Chin, E. Ratner, S. Leng et al., “A SNP in a let-7 microRNA complementary site in the KRAS untranslated region increases non-small cell lung cancer risk,” Cancer Research, vol. 68, no. 20, pp. 8535–8540, 2008.
- A. Hollestelle, C. Pelletier, M. Hooning et al., “Prevalence of the variant allele rs61764370 T>G in the UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families,” Breast Cancer Research and Treatment, vol. 128, no. 1, pp. 79–84, 2011.
- K. M. Smits, T. Paranjape, S. Nallur, et al., “A let-7 microRNA SNP in the KRAS UTR is prognostic in early-stage colorectal cancer,” Clinical Cancer Research, vol. 17, no. 24, pp. 7723–7731, 2011.
- E. Chan, R. Patel, S. Nallur, et al., “MicroRNA signatures differentiate melanoma subtypes,” Cell Cycle, vol. 10, no. 11, pp. 1854–1852, 2011.
- B. C. Christensen, B. J. Moyer, M. Avissar et al., “A let-7 microRNA-binding site polymorphism in the KRAS UTR is associated with reduced survival in oral cancers,” Carcinogenesis, vol. 30, no. 6, pp. 1003–1007, 2009.
- E. S. Ratner, F. K. Keane, R. Lindner, et al., “A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer,” Oncogene, vol. 31, no. 42, pp. 4559–4566, 2012.
- J. B. Kjersem, T. Ikdahl, T. Guren, et al., “Let-7 miRNA-binding site polymorphism in the KRAS UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab,” BMC Cancer, vol. 12, no. 1, pp. 534–541, 2012.
- H. H. Nelson, B. C. Christensen, S. L. Plaza, J. K. Wiencke, C. J. Marsit, and K. T. Kelsey, “KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer,” Lung Cancer, vol. 69, no. 1, pp. 51–53, 2010.
- J. Permuth-Wey, Z. Chen, Y. Y. Tsai, et al., “MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium,” Cancer Epidemiology, Biomarkers & Prevention, vol. 20, no. 8, pp. 1793–1797, 2011.
- M. S. Nicoloso, H. Sun, R. Spizzo et al., “Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility,” Cancer Research, vol. 70, no. 7, pp. 2789–2798, 2010.
- L. Valle, T. Serena-Acedo, S. Liyanarachchi et al., “Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer,” Science, vol. 321, no. 5894, pp. 1361–1365, 2008.
- F. Xiong, C. Wu, J. Chang et al., “Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer,” Cancer Research, vol. 71, no. 15, pp. 5175–5181, 2011.
- Y. Jiang, Z. Qin, Z. Hu, et al., “Genetic variation in a hsa-let-7 binding site in RAD52 is associated with breast cancer susceptibility,” Carcinogenesis, 2012.
- F. Song, H. Zheng, B. Liu et al., “An miR-502-binding site single-nucleotide polymorphism in the -untranslated region of the SET8 gene is associated with early age of breast cancer onset,” Clinical Cancer Research, vol. 15, no. 19, pp. 6292–6300, 2009.
- X. Shi, I. Kachirskaia, H. Yamaguchi et al., “Modulation of p53 function by SET8-mediated methylation at lysine 382,” Molecular Cell, vol. 27, no. 4, pp. 636–646, 2007.
- Z. Guo, C. Wu, X. Wang, C. Wang, R. Zhang, and B. Shan, “A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome,” International Journal of Cancer, vol. 131, no. 5, pp. 1318–1322, 2012.
- C. Ding, R. Li, J. Peng, S. Li, and Z. Guo, “A polymorphism at the miR-502 binding site in the untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer,” Experimental and Therapeutic Medicine, vol. 3, no. 4, pp. 689–692, 2012.
- C. Wang, Z. Guo, C. Wu, Y. Li, and S. Kang, “A polymorphism at the miR-502 binding site in the 3’ untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer,” Cancer Genetics, vol. 205, no. 7-8, pp. 373–376, 2012.
- X. Guan, Z. Liu, H. Liu, et al., “A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer,” The FASEB Journal, 2012.
- D. Landi, F. Gemignani, A. Naccarati et al., “Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer,” Carcinogenesis, vol. 29, no. 3, pp. 579–584, 2008.
- D. Landi, V. Moreno, E. Guino, et al., “Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer,” Mutation Research, vol. 717, no. 1-2, pp. 109–115, 2011.
- L. Zhang, Y. Liu, F. Song, et al., “Functional SNP in the microRNA-367 binding site in the UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification,” Proceedings of the National Academy of Science of the United States of America, vol. 108, no. 33, pp. 13653–13658, 2011.
- J. Luo, Q. Cai, W. Wang, et al., “A microRNA-7 binding site polymorphism in HOXB5 leads to differential gene expression in bladder cancer,” PLoS ONE, vol. 7, no. 6, Article ID e40127, 2012.
- J. Wynendaele, A. Böhnke, E. Leucci et al., “An illegitimate microRNA target site within the UTR of MDM4 affects ovarian cancer progression and chemosensitivity,” Cancer Research, vol. 70, no. 23, pp. 9641–9649, 2010.
- B. M. Ryan, A. I. Robles, and C. C. Harris, “Genetic variation in microRNA networks: the implications for cancer research,” Nature Reviews Cancer, vol. 10, no. 6, pp. 389–402, 2010.
- M. S. Kim, J. E. Oh, Y. R. Kim et al., “Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers,” Journal of Pathology, vol. 221, no. 2, pp. 139–146, 2010.
- Y. Horikawa, C. G. Wood, H. Yang et al., “Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma,” Clinical Cancer Research, vol. 14, no. 23, pp. 7956–7962, 2008.
- J. Lin, Y. Horikawa, P. Tamboli, J. Clague, C. G. Wood, and X. Wu, “Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma,” Carcinogenesis, vol. 31, no. 10, pp. 1805–1812, 2010.
- H. Sung, S. Jeon, K. M. Lee, et al., “Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival,” BMC Cancer, vol. 12, article 195, 2012.
- J. Liu, J. Liu, M. Wei, et al., “Genetic variants in the microRNA machinery gene GEMIN4 are associated with risk of prostate cancer: a case-control study of the Chinese Han population,” DNA and Cell Biology, vol. 31, no. 7, pp. 1296–1302, 2012.
- M. Campayo, A. Navarro, N. Viñolas et al., “A dual role for KRT81: an miR-SNP associated with recurrence in Non-Small-Cell lung cancer and a novel marker of squamous cell lung carcinoma,” PLoS ONE, vol. 6, no. 7, Article ID e22509, 2011.
- H. Ma, H. Yuan, Z. Yuan, et al., “Genetic variations in key microRNA processing genes and risk of head and neck cancer: a case-control study in Chinese population,” PLoS ONE, vol. 7, no. 10, Article ID e47544, 2012.
- C. F. de Larrea, A. Navarro, R. Tejero, et al., “Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation,” Clinical Cancer Research, vol. 18, no. 13, pp. 3697–3704, 2012.